Physician profile
David Ross Paskil
NPI 1942228697
$661.97
in general payments reported to CMS, 2019-2025
14 companies · $25.92 in 2025
The $25.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $82.02 · 2023: $144 · 2025: $25.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $199.67 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $120.39 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $54.02 | 2019-2020 | |
| Pfizer INC. | $53.94 | 2019-2020 | |
| Lilly USA, LLC | $52.11 | 2019-2025 | Kisunla |
| Therapeuticsmd, INC. | $35.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.78 | 2019 | |
| Medtronic, INC. | $23.56 | 2023 | Intellis Adaptivestim |
| Novo Nordisk INC | $21.21 | 2019 | |
| Boston Scientific Corporation | $20.32 | 2019 | |
| Astellas Pharma US INC | $16.59 | 2019 | |
| Sanofi Pasteur INC. | $13.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.10 | 2019 | |
| Seqirus USA INC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Paskil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.